Scaling up interventions to achieve global tuberculosis control: progress and new developments (Q38011369)

26 August 2017

Scaling up interventions to achieve global tuberculosis control: progress and new developments (English)

1 reference

26 August 2017

0 references

15

1 reference

Giovanni Battista Migliori

26 August 2017

Mario Raviglione

1

0 references

object named as

Giovanni B Migliori

6

0 references

Stefan Kaufmann

object named as

Stefan H E Kaufmann

14

0 references

Knut Lönnroth

4

object named as

Knut Lönnroth

1 reference

26 August 2017

7

Anthony D Harries

1 reference

26 August 2017

9

Christian Lienhardt

1 reference

26 August 2017

13

Stewart Cole

1 reference

26 August 2017

Ben Marais

2

1 reference

26 August 2017

Katherine Floyd

3

1 reference

26 August 2017

Haileyesus Getahun

5

1 reference

26 August 2017

Paul Nunn

8

1 reference

26 August 2017

Steve Graham

10

1 reference

26 August 2017

Jeremiah Chakaya

11

1 reference

26 August 2017

Karin Weyer

12

1 reference

26 August 2017

language of work or name

English

0 references

publication date

1 May 2012

1 reference

26 August 2017

1 reference

26 August 2017

379

1 reference

26 August 2017

1902-1913

1 reference

26 August 2017

9829

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

26 August 2017

1 reference

7 January 2021

Tuberculosis in the UK--time to regain control

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Scale-up of services and research priorities for diagnosis, management, and control of tuberculosis: a call to action

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Lives saved by tuberculosis control and prospects for achieving the 2015 global target for reducing tuberculosis mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Timing of antiretroviral therapy for HIV-1 infection and tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Integration of antiretroviral therapy with tuberculosis treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)--associated tuberculous meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Protease inhibitor-containing antiretroviral treatment and tuberculosis: can rifabutin fill the breach?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Symptom screening among HIV-infected pregnant women is acceptable and has high negative predictive value for active tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Treatment of latent tuberculosis infection in HIV infected persons

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

New regimens to prevent tuberculosis in adults with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Antiretroviral therapy and TB notification rates in a high HIV prevalence South African community

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Completion of isoniazid preventive therapy and survival in HIV-infected, TST-positive adults in Tanzania

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

MDR tuberculosis--critical steps for prevention and control

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Drug-resistant tuberculosis--current dilemmas, unanswered questions, challenges, and priority needs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

The Global Fund Round 11 cancellation fiasco: turning disaster into opportunity?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Totally drug-resistant tuberculosis in India.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Rational use of anti-tuberculosis drugs in the EU: better patient care and less drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Emergence and treatment of multidrug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis in South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Maternal tuberculosis: a risk factor for mother-to-child transmission of human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Impact of tuberculosis exposure at home on mortality in children under 5 years of age in Guinea-Bissau

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Epidemiology of tuberculosis among US- and foreign-born children and adolescents in the United States, 1994-2007

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Accuracy of the Xpert MTB/RIF test for the diagnosis of pulmonary tuberculosis in children admitted to hospital in Cape Town, South Africa: a descriptive study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Xpert MTB/RIF for rapid diagnosis of tuberculous lymphadenitis from fine-needle-aspiration biopsy specimens

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Evaluation of tuberculosis diagnostics in children: 1. Proposed clinical case definitions for classification of intrathoracic tuberculosis disease. Consensus from an expert panel.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Evaluation of tuberculosis diagnostics in children: 2. Methodological issues for conducting and reporting research evaluations of tuberculosis diagnostics for intrathoracic tuberculosis in children. Consensus from an expert panel

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Paediatric use of second-line anti-tuberculosis agents: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

TB and M/XDR-TB infection control in European TB reference centres: the Achilles' heel?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Tuberculosis management by private practitioners in Mumbai, India: has anything changed in two decades?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Size and usage patterns of private TB drug markets in the high burden countries

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Comparison of the Xpert MTB/RIF test with an IS6110-TaqMan real-time PCR assay for direct detection of Mycobacterium tuberculosis in respiratory and nonrespiratory specimens

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Rapid molecular detection of tuberculosis and rifampin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Evaluation of the Cepheid Xpert MTB/RIF assay for direct detection of Mycobacterium tuberculosis complex in respiratory specimens

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Immunological biomarkers of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Dominant TNF-α+ Mycobacterium tuberculosis–specific CD4+ T cell responses discriminate between latent infection and active disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

The immunological footprint of Mycobacterium tuberculosis T-cell epitope recognition

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Human gene expression profiles of susceptibility and resistance in tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Host biomarkers of clinical relevance in tuberculosis: review of gene and protein expression studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Common patterns and disease-related signatures in tuberculosis and sarcoidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

New tuberculosis drugs on the horizon

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Three months of rifapentine and isoniazid for latent tuberculosis infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Challenges of Phase III study design for trials of new drug regimens for the treatment of TB.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Innovative Trial Designs Are Practical Solutions for Improving the Treatment of Tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

A multistage tuberculosis vaccine that confers efficient protection before and after exposure.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

New vaccines for tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Immunogenicity of the Tuberculosis Vaccine MVA85A Is Reduced by Coadministration with EPI Vaccines in a Randomized Controlled Trial in Gambian Infants

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Fact and fiction in tuberculosis vaccine research: 10 years later

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyperconserved

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Functional genetic diversity among Mycobacterium tuberculosis complex clinical isolates: delineation of conserved core and lineage-specific transcriptomes during intracellular survival

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Comparative genomics of Esx genes from clinical isolates of Mycobacterium tuberculosis provides evidence for gene conversion and epitope variation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Human macrophage responses to clinical isolates from the Mycobacterium tuberculosis complex discriminate between ancient and modern lineages

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Simple model for testing drugs against nonreplicating Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Pristinamycin-inducible gene regulation in mycobacteria.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Protein inactivation in mycobacteria by controlled proteolysis and its application to deplete the beta subunit of RNA polymerase.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Depletion of antibiotic targets has widely varying effects on growth

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Building leadership capacity and future leaders in operational research in low-income countries: why and how?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Two-thirds of smear-positive tuberculosis cases in the community were undiagnosed in Northwest Ethiopia: population based cross-sectional study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

High prevalence of subclinical tuberculosis in HIV-1-infected persons without advanced immunodeficiency: implications for TB screening

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

European union standards for tuberculosis care

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Modeling social, environmental and biological determinants of tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Risk factors associated with pulmonary tuberculosis: smoking, diabetes and anti-TNFα drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Comparison of two active case-finding strategies for community-based diagnosis of symptomatic smear-positive tuberculosis and control of infectious tuberculosis in Harare, Zimbabwe (DETECTB): a cluster-randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

Tuberculosis and noncommunicable diseases: neglected links and missed opportunities.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

A global framework for action to improve the primary care response to chronic non-communicable diseases: a solution to a neglected problem

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

A sustainable agenda for tuberculosis control and research

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960727-2

7 January 2021

10.1016/S0140-6736(12)60727-2

Identifiers

DOI

1 reference

26 August 2017

1 reference